Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Geen verhoogd risico op andere kanker bij lynchsyndroom
sep 2018 | Gynaecologische oncologie, Maag-darm-leveroncologie